BIOCON · NSE
Biocon Limited
₹364.4
+0.21% (+₹0.75)
Prev. close
₹363.65
Volume
14,76,514
Delivery %
53.1%
As of
20 Nov 2026
Price history
Analyst sentiment
Analysts lean bullish
2 analyst stances · last 90 days · one per analyst
Trackable
2 · 2 bull / 0 neutral / 0 bear
Long-Horizon
none in range
Commentary
none in range
Trackable = verdict-bearing calls · Long-Horizon = 1yr+ horizon, verdict pending · Commentary = context, not graded
Analyst opinions
| Call | Analyst | Instrument | Verdict | Actions |
|---|---|---|---|---|
| “Axis Direct is bullish on Biocon, assigning a buy rating and a target of ₹485, citing robust earnings and growth prospec…” | ETMarkets AnalysisETMarkets.com | Biocon | PENDING | |
| “Recommends buying Biocon in the range of ₹345-₹350, targeting ₹370 with a stop-loss at ₹330. This is a near-term trading…” | Ganesh DongreAnand Rathi | Biocon | HIT | |
| “Bullish on Biocon, recommending a buy at CMP ₹426.8 with a target of ₹470 and a stop-loss at ₹405. The stock has confirm…” | Ajit MishraReligare Broking | Biocon | MISS | |
| “Axis recommends Biocon as a technical buy for May, targeting ₹427-448 (11.4% upside) from a buying range of ₹375-385, wi…” | Axis Securities AnalysisAxis Securities | Biocon | NOT TRIGGERED | |
| “Recommends buying Biocon at ₹410 for intraday trading, with a target of ₹432 and a stop loss at ₹400.” | Vaishali ParekhPrabhudas Lilladher | Biocon | NOT TRIGGERED | |
| “Bullish on Biocon, which has rebounded strongly from an upward-sloping trendline and broken above its recent swing high …” | Rajesh PalviyaAxis Securities | Biocon | HIT | |
| “Bullish on Biocon for the short term (1-2 weeks), with a target price of ₹418 and a stop loss at ₹369. The stock has sho…” | Ajit MishraReligare Broking | Biocon | HIT | |
| “Initiated coverage on Biocon with a 'Buy' rating and a target price of Rs 410, implying a 13% upside from the current ma…” | Motilal Oswal AnalysisMotilal Oswal Financial Services | Biocon | HIT | |
| “Recommends buying Biocon Ltd around ₹383, with a stop loss at ₹370 and a target price of ₹405 in the near term. The stoc…” | Ganesh DongreAnand Rathi | Biocon | MISS | |
| “Bullish on Biocon, recommending a buy at ₹398 with a stop loss at ₹390 for a near-term target price of ₹415. The stock s…” | Ganesh DongreAnand Rathi | Biocon | MISS | |
| “Recommends buying Biocon Ltd between ₹380-395, targeting ₹454 in two to three months with a stop loss at ₹368. The call …” | Marketsmith India AnalysisMarketsmith India | Biocon | MISS | |
| “Bullish on Biocon, recommending a buy with a target price of ₹404 and a stop loss at ₹366. The stock is retesting a brea…” | Chandan TapariaMotilal Oswal Financial Services Ltd | Biocon | MISS | |
| “Bullish on Biocon, recommending buying at current market price and on dips towards ₹370, with a target of ₹400. This is …” | CA Rudramurthy BVVachana Investments | Biocon | HIT | |
| “Recommends buying Biocon with a target of ₹390 and a stop loss at ₹374, indicating a short-term bullish outlook.” | Kunal BothraIndependent | Biocon | PENDING | |
| “Bullish on Biocon, recommending a buy with a target price of ₹395 and a stop loss at ₹360. The stock has broken out of a…” | Chandan TapariaMotilal Oswal Financial Services Ltd | Biocon | PENDING | |
| “Bullish on Biocon Ltd, recommending a buy above ₹363 and dips to ₹355, with a target price of ₹374-385 in 1 month. The c…” | Raja VenkatramanNeoTrader | Biocon | HIT | |
| “Recommends buying BIOCON above ₹363 and on dips to ₹355, with a stop loss at ₹353 and a target of ₹374-378 for July 2nd.…” | Raja VenkatramanNeoTrader | Biocon | PENDING | |
| “Bullish on Biocon for the next two to three weeks, targeting ₹385 with a stop loss at ₹332. The stock established a robu…” | Jigar S. PatelAnand Rathi Share and Stock Brokers | Biocon | MISS | |
| “Bullish on Biocon, recommending a buy at ₹356 with a target of ₹385 and a stop-loss at ₹344. The stock has broken out of…” | Rupak DeLKP Securities | Biocon | MISS | |
| “Recommends buying Biocon shares for the next two to three weeks, targeting ₹390 with a stop loss at ₹335. The stock brok…” | Jigar S. PatelAnand Rathi Share and Stock Brokers | Biocon | MISS | |
| “Bullish on Biocon with a target of ₹370 and a stop loss at ₹346, for traders with a short-term horizon.” | Kunal BothraIndependent | Biocon | MISS | |
| “Maintains a 'Sell' call on Biocon with a revised target price of ₹270, down from the current market price of ₹334.4. Des…” | ICICI Securities AnalysisICICI Securities | Biocon | MISS | |
| “Axis Securities recommends a Buy call on Biocon, setting a target price of Rs 351, indicating a potential 10% upside ove…” | Axis Securities AnalysisAxis Securities | Biocon | PENDING | |
| “Bullish on Biocon, recommending a buy with a target of ₹332 and a stop loss at ₹315 for short-term trading.” | Kunal BothraIndependent | Biocon | HIT | |
| “Bullish on Biocon Ltd, recommending a buy at ₹334 with a target price of ₹348 and a stop loss at ₹325. A notable bullish…” | Ganesh DongreAnand Rathi | Biocon | MISS | |
| “Recommends buying Biocon with a target of ₹332 and a stop loss at ₹304 for a short-term trading horizon.” | Nagaraj ShettiHDFC Securities | Biocon | PENDING | |
| “Bullish on Biocon Ltd, recommending a buy above ₹391 with a target of ₹425 and a stop loss at ₹375. A strong case of bul…” | Raja VenkatramanNeoTrader | Biocon | PENDING | |
| “Recommends buying Biocon above ₹391, with a stop loss at ₹375 and a target of ₹425. A strong case of bullishness is seen…” | Raja VenkatramanNeoTrader | Biocon | MISS | |
| “Bullish on Biocon Ltd, recommending a buy at ₹364 with a stop loss at ₹354 for a target price of ₹380. A notable bullish…” | Ganesh DongreAnand Rathi | Biocon | MISS | |
| “Bullish on Biocon with a short-term target of ₹420 and recommends a stop loss at ₹390.” | Kunal BothraIndependent | Biocon | MISS | |
| “Bullish on Biocon, recommending a buy at ₹401.55 with targets of ₹428-435 and a stop loss at ₹386. The stock shows a str…” | Ankush BajajIndependent | Biocon | PENDING | |
| “Recommends buying Biocon at ₹401.55 with targets of ₹428-435 and a stop loss at ₹386. The stock shows a strong bullish t…” | Ankush BajajIndependent | Biocon | PENDING | |
| “Recommends buying Biocon at ₹393 with a target price of ₹410 and a stop loss of ₹380 for intraday trading.” | Vaishali ParekhPrabhudas Lilladher | Biocon | MISS | |
| “Motilal Oswal Financial Services has upgraded Biocon to a 'Buy' with a target price of Rs 430, based on a 12-month forwa…” | Motilal Oswal AnalysisMotilal Oswal Financial Services | Biocon | MISS | |
| “Bullish on Biocon Ltd, recommending a buy with a target of ₹450 and a stop loss at ₹370 for a short-term trading horizon…” | Nooresh MeraniIndependent | Biocon | MISS | |
| “Bullish on Biocon Ltd; recommends buying at ₹389 with a stop loss at ₹380 and a target of ₹410. The pharma counter has h…” | Raja VenkatramanNeoTrader | Biocon | MISS | |
| “Bullish on Biocon, recommending a buy at ₹387.65 with a target of ₹420-435 and a stop loss at ₹370. Despite broader mark…” | Ankush BajajIndependent | Biocon | MISS | |
| “Recommends buying Biocon in the ₹375–390 range, targeting ₹458 with a stop loss at ₹350, over a 2–3 month timeframe. The…” | Marketsmith India AnalysisMarketsmith India | Biocon | MISS | |
| “Upgraded Biocon to a 'Buy' rating with a target price of ₹430 per share, emphasizing that the Malaysian site achieved 'V…” | Motilal Oswal AnalysisMotilal Oswal Financial Services | Biocon | MISS | |
| “Recommends buying Biocon with a target of Rs 382 and a stop loss at Rs 354, indicating a short-term bullish view.” | Ajit MishraReligare Broking | Biocon | PENDING | |
| “Recommends buying Biocon Ltd with a target of Rs 388 and a stop loss at Rs 357, indicating a short-term bullish view.” | Kunal BothraIndependent | Biocon | HIT | |
| “Maintained "Buy" rating on Biocon, raising the target price to Rs 435 from Rs 400, implying a potential upside of 20% fr…” | Private Bank Trader AnalysisPrivate Bank Trader | Biocon | MISS | |
| “Upgraded Biocon's stock rating to 'Hold' with a revised target price of ₹400, citing positive developments including the…” | Jefferies AnalysisJefferies | Biocon | HIT | |
| “Upgraded Biocon to 'Hold' from 'Underperform' and raised the target price to Rs 400 from Rs 280, indicating an 11% upsid…” | Jefferies AnalysisJefferies | Biocon | HIT |
Market commentary · 11 · levels, conditionals, previews, macro & hedged views — context, not graded
| Call | Analyst | Instrument | Verdict | Actions |
|---|---|---|---|---|
| “Baliga is bullish on Biocon, identifying it as a top pick and a major beneficiary in the pharma sector. He notes a techn…” | Ambareesh BaligaIndependent | Biocon Limited | — | |
| “Nischal Maheshwari remains positive on Biocon, believing the proposed QIP will ease balance sheet pressure by funding th…” | Nischal MaheshwariIndependent | Biocon | — | |
| “Bullish on Biocon, expecting another 10-15% upside from current levels, with a fair value close to ₹500. This outlook is…” | Nikhil RankaNuvama Asset Management | Biocon | — | |
| “Bullish on Biocon (BIOCON), suggesting to go long above ₹385 with a target price of ₹379 and a stop loss at ₹393. The st…” | Raja VenkatramanNeoTrader | Biocon | — | |
| “Recommends buying Biocon at current market price, targeting an initial level of 400, with a stop loss at 365. This call …” | CA Rudramurthy BVVachana Investments | Biocon | — | |
| “HSBC maintains a 'buy' rating on Biocon shares, following a significant boost from a ₹4,500 crore Qualified Institutiona…” | HSBC AnalysisHSBC | Biocon | — | |
| “Bullish on Biocon, recommending a buy in the range of ₹375–390 with a profit goal of ₹458 and a stop loss of ₹350, over …” | Marketsmith India AnalysisMarketsmith India | Biocon | — | |
| “Upgraded Biocon to a 'Hold' rating from 'Underperform' and increased its price target to ₹400 from ₹280. The brokerage n…” | Jefferies AnalysisJefferies | Biocon | — | |
| “Bullish on Biocon for the short term, with a target range of ₹403-436 in the next few weeks. The stock has broken out fr…” | ETMarkets AnalysisETMarkets.com | Biocon | — | |
| “Recommends buying Biocon Ltd. within the range of ₹370–385, targeting a profit goal of ₹458 with a stop loss at ₹348. Th…” | Marketsmith India AnalysisMarketsmith India | Biocon | — | |
| “Upgraded Biocon from 'Underperform' to 'Hold' with a revised target price of ₹400, up from ₹280. This reflects a more po…” | Jefferies AnalysisJefferies | Biocon | — |
Fundamentals
About Biocon Limited
Biocon Limited, together with its subsidiaries, manufactures biotechnology products and offers research services in India, the United States, Ireland, rest of the European Union, and internationally. It operates through Generics; Biosimilars; and Contract Research, Development and Manufacturing Organization (CRDMO) segments. The company offers generic formulations and API products, including cardiovascular, anti-diabetics, obesity, central nervous system, anti-cancer/oncology, multiple sclerosis, immunosuppressants, and specialty molecules; and biosimilars products for oncology, diabetes, and immunology therapeutic areas. It also provides integrated discovery, development, and manufacturing services to pharmaceutical, biotechnology, animal health, consumer goods, and specialty chemical industries, as well as academic institutions, non-profit organizations, and government agencies. In addition, the company offers enzyme, biopharmaceutical, and medicinal goods; contract research and manufacturing services; clinical research; and business support and development, and marketing services. Biocon Limited was incorporated in 1978 and is headquartered in Bengaluru, India.
Details
Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Shreehas Pradeep Tambe MTech
Headquarters
Bengaluru
Employees
16,447
Website
biocon.comExchange
View on NSE ↗Key stats
Market cap
₹56,109.45 Cr
P/E ratio (TTM)
101.4
Dividend yield
0.15%
EPS (TTM)
₹3.38
Beta (1Y · daily vs NIFTY 50)
0.64
Beta (5Y · monthly vs NIFTY 50)
0.99
Shares float
81.94 Cr
EPS · quarter ended Jun 2026
₹0.87
Financial Performance
01 · Financials
02 · Earnings Per Share (EPS)
03 · Dividend Profile
Growth compares completed fiscal-year dividend totals on the company's own calendar: April–March (Indian FY), taken from its reported period-ends. Payout ledger: NSE corporate actions.
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based
05 · Capital Structure & Asset Utilization
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
07 · Debt Level & Coverage
08 · Profit & Loss
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹7,105.80 Cr | ₹8,184.00 Cr | ₹11,174.20 Cr | ₹14,755.70 Cr | ₹15,261.70 Cr | ₹16,927.00 Cr | |
EBITDA | ₹1,919.70 Cr | ₹2,071.80 Cr | ₹2,429.20 Cr | ₹4,068.40 Cr | ₹4,471.00 Cr | ₹3,394.90 Cr |
| ₹740.50 Cr | ₹648.40 Cr | ₹462.70 Cr | ₹1,022.50 Cr | ₹1,013.30 Cr | ₹385.60 Cr | |
Diluted EPS | ₹6.19 | ₹5.42 | ₹3.87 | ₹8.54 | ₹8.46 | ₹2.82 |
09 · Balance Sheet
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹18,490.00 Cr | ₹20,342.00 Cr | ₹51,742.00 Cr | ₹55,753.00 Cr | ₹58,540.00 Cr | ₹63,409.00 Cr | |
| ₹4,481.10 Cr | ₹5,146.60 Cr | ₹18,018.80 Cr | ₹16,276.70 Cr | ₹18,362.00 Cr | ₹15,434.10 Cr | |
Stockholders' equity | ₹7,627.00 Cr | ₹8,432.00 Cr | ₹17,867.00 Cr | ₹19,783.00 Cr | ₹21,644.00 Cr | ₹34,031.00 Cr |
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹1,160.00 Cr | ₹1,177.00 Cr | ₹1,852.00 Cr | ₹2,954.00 Cr | ₹4,061.00 Cr | ₹1,994.00 Cr | |
Investing cash flow | ₹-3,624.70 Cr | ₹-1,699.10 Cr | ₹-14,281.80 Cr | ₹-1,004.50 Cr | ₹-234.10 Cr | ₹-2,082.10 Cr |
| ₹2,564.00 Cr | ₹242.00 Cr | ₹13,049.00 Cr | ₹-2,333.00 Cr | ₹-1,854.00 Cr | ₹-924.00 Cr | |
Capital expenditure | ₹-1,746.30 Cr | ₹-6,226.80 Cr | ₹-1,726.30 Cr | ₹-1,931.60 Cr | ₹-2,343.30 Cr | ₹-1,911.70 Cr |
End cash position | — | ₹653.70 Cr | ₹1,294.80 Cr | ₹919.50 Cr | ₹2,923.80 Cr | ₹2,111.50 Cr |
End cash position has filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source has no quarterly cash-flow-statement coverage.
11 · Shareholding Pattern
NSE, quarterly
| Line item | Sep 21 | Dec 21 | Mar 22 | Jun 22 | Sep 22 | Dec 22 | Mar 23 | Jun 23 | Sep 23 | Dec 23 | Mar 24 | Jun 24 | Sep 24 | Dec 24 | Mar 25 | Jun 25–Jun 25(2Q) | Sep 25 | Dec 25 | Jan 26 | Jan 26 | Mar 26 | Jun 26–Jun 26(2Q) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 60.64% | 60.64% | 60.64% | 60.64% | 60.64% | 60.64% | 60.64% | 60.64% | 60.64% | 60.64% | 60.64% | 60.64% | 60.64% | 60.64% | 60.64% | 54.45% | 54.45% | 54.45% | 48.27% | 44.91% | 44.91% | 44.68% |
| Public | 38.64% | 38.71% | 38.74% | 38.63% | 38.74% | 38.78% | 38.81% | 38.87% | 38.97% | 39.03% | 39.05% | 39.08% | 39.12% | 39.14% | 39.15% | 45.37% | 45.41% | 45.43% | 51.63% | 54.99% | 55.00% | 55.27% |
| Employee trusts | 0.72% | 0.65% | 0.63% | 0.73% | 0.63% | 0.58% | 0.55% | 0.49% | 0.39% | 0.33% | 0.32% | 0.28% | 0.25% | 0.22% | 0.21% | 0.18% | 0.14% | 0.12% | 0.10% | 0.10% | 0.09% | 0.05% |
Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.25 L Cr | ₹1,769.9 | 38.8 | 5.09 | 13.7% | 0.06 | +11.9% | +3.7% |
| Divi's Laboratories Limited | ₹2.66 L Cr | ₹10,037.5 | 90.8 | 15.85 | 15.3% | 0.00 | +12.3% | +47.5% |
| Torrent Pharmaceuticals Limited | ₹1.79 L Cr | ₹4,738.5 | 79.4 | 21.31 | 25.8% | 1.79 | +21.5% | +32.5% |
| Laurus Labs Limited | ₹1.27 L Cr | ₹2,348 | 94.8 | 23.94 | 16.8% | 0.48 | +22.0% | +146.2% |
| Apollo Hospitals Enterprise Limited | ₹1.23 L Cr | ₹8,599.5 | 58.8 | 12.95 | 20.5% | 0.90 | +15.7% | +10.1% |
| Zydus Lifesciences Limited | ₹1.19 L Cr | ₹1,188.1 | 26.7 | 4.40 | 18.6% | 0.46 | +18.4% | +22.3% |
| Lenskart Solutions Limited | ₹1.16 L Cr | ₹689.7 | 181.4 | 13.30 | 5.6% | 0.35 | +35.4% | — |
| Dr. Reddy's Laboratories Limited | ₹1.14 L Cr | ₹1,374 | 40.6 | 3.02 | 11.4% | 0.21 | +3.2% | +14.5% |
| Cipla Limited | ₹1.13 L Cr | ₹1,402 | 38.9 | 3.27 | 11.3% | 0.02 | +2.1% | -6.7% |
| Mankind Pharma Limited | ₹1.03 L Cr | ₹2,475 | 45.9 | 6.31 | 11.7% | 0.39 | +17.0% | +3.1% |
| Aurobindo Pharma Limited | ₹98,101.93 Cr | ₹1,705 | 26.6 | 2.59 | 9.2% | 0.21 | +6.4% | +48.4% |
| Biocon Limited | ₹56,109.45 Cr | ₹344.45 | 101.4 | 1.65 | 1.1% | 0.45 | +11.5% | -9.5% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.